Get started
Author

Rodney A. Prell

Observed names: R A Prell, R. Prell, R.A. Prell, Rodney A Prell, Rodney Prell, Rodney A. Prell
Institution: Genentech
ORCID: 0000-0002-4762-2937
Observed ORCID: 0000-0002-4762-2937
OpenAlex ID: A5081183519
Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity
2000 · Andrew D Weinberg, Martin-Muy Rivera, et al. · The Journal of Immunology · 387
PDF
A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
2011 · Gabriele Schaefer, Lauric Haber, et al. · Cancer Cell · 341
PDF
Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF–Secreting Cancer Immunotherapy
2006 · Betty Li, Alshad S. Lalani, et al. · Clinical Cancer Research · 232
Danger and OX40 Receptor Signaling Synergize to Enhance Memory T Cell Survival by Inhibiting Peripheral Deletion
2000 · Joseph R Maxwell, Andrew Weinberg, et al. · The Journal of Immunology · 219
PDF
An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
2016 · Steven R. Leong, Siddharth Sukumaran, et al. · Blood · 155
Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
2018 · Dionysos Slaga, Diego Ellerman, et al. · Science Translational Medicine · 138
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody
2020 · Karin Staflin, Christina L. Zuch de Zafra, et al. · JCI Insight · 106
PDF
Cytokine release assays: Current practices and future directions
2014 · D. Finco, C. Grimaldi, et al. · Cytokine · 106
Engagement of OX40 Enhances Antigen-Specific CD4+ T Cell Mobilization/Memory Development and Humoral Immunity: Comparison of αOX-40 with αCTLA-4
2001 · Dean E Evans, Rodney A Prell, et al. · The Journal of Immunology · 94
PDF
OX40-Mediated Memory T Cell Generation Is TNF Receptor-Associated Factor 2 Dependent
2003 · Rodney A Prell, Dean E Evans, et al. · The Journal of Immunology · 79
PDF
Efficacy of GM-CSF-producing Tumor Vaccine after Docetaxel Chemotherapy in Mice Bearing Established Lewis Lung Carcinoma
2006 · Yiwei Chu, Li-Xin Wang, et al. · Journal of Immunotherapy · 69
The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement
2004 · Andrew D Weinberg, Dean E Evans, et al. · Journal of Leukocyte Biology · 56
Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on anti-CD3-induced changes in T-cell subsets and cytokine production
1995 · R.A. Prell, J.A. Oughton, et al. · International Journal of Immunopharmacology · 45
Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma
1997 · R A Prell, N I Kerkvliet · The Journal of Immunology · 35
The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration
2006 · Rodney A. Prell, Lisa Gearin, et al. · Cancer Immunology Immunotherapy · 31
Activation of Immature Hepatic NK Cells As Immunotherapy for Liver Metastatic Disease
2007 · Keith S Bahjat, Rodney A Prell, et al. · The Journal of Immunology · 24
Administration of IFN-α Enhances the Efficacy of a Granulocyte Macrophage Colony Stimulating Factor–Secreting Tumor Cell Vaccine
2005 · Rodney A. Prell, Betty Li, et al. · Cancer Research · 22
CTL Hyporesponsiveness Induced by 2,3,7,8-Tetrachlorodibenzo-p-dioxin: Role of Cytokines and Apoptosis
2000 · Rodney A. Prell, Erica Dearstyne, et al. · Toxicology and Applied Pharmacology · 21
Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy
2016 · Rodney A. Prell, Wendy G. Halpern, et al. · International Journal of Toxicology · 13
PDF
Assessing the impact and risk of immunomodulatory compounds on pregnancy
2025 · Joanne Kwak-Kim, Curtis C. Maier, et al. · Journal of Reproductive Immunology · 9
Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys
2018 · Rodney A Prell, Noel Dybdal, et al. · Toxicological Sciences · 9
Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics
2022 · Christine Grimaldi, Alex Ibraghimov, et al. · Drug Discovery Today · 7
Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?
2022 · Songmao Zheng, Rodney Prell, et al. · Clinical and Translational Science · 7
In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection
2019 · Gautham K Rao, Rodney A Prell, et al. · Toxicological Sciences · 5
Developmental Immunotoxicology Testing (DIT)
2017 · M. Holsapple, R. Prell, et al. · Elsevier eBooks · 3
Works count: 41
Citation count: 2,224
H-index: 18
I10-index: 19
Year
Topic
Type